Skip to content

The efficacy and safety of intraarticalar hyaluronan injection in knee and physical therapy agents for Kashin Beck disease: intervention study

The efficacy and safety of intraarticalar hyaluronan injection for Kashin Beck disease

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-12002189
Enrollment
Unknown
Registered
2012-05-07
Start date
2008-05-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kashin Beck disease

Interventions

2:hyaluronan

Sponsors

the International Co-operative Fund in Shaanxi, China and Finland
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
42 Years to 71 Years

Inclusion criteria

Inclusion criteria: All patients had grades II knee KBD confirmed radiologically according to the analysis of X-ray films of the right hand, knee and hip joints. All patients suffered pain in the affected knee continued for at least 6 months. Baseline characteristics (weight, height, age, sex and related knee and radiological degree) were recorded before the treatment. Laboratory assessment (according to standard methods) made at the entry and after 6 months included the following evaluation: routine hematological variables, functional tests of kidney and liver.

Exclusion criteria

Exclusion criteria: Patients were excluded from the study if they had received intra-articular injections in the joint or/and attend physiotherapy for the affected knee, to be applied within the 6 months prior to study, if they had a history of allergy or hypersensitive to drugs or eggs, or if they were ascertained or suspected to be pregnant or lactating. Patients were also excluded if they had a known or suspected joint infection or a specific condition (neoplasm, diabetes mellitus, paresis, osteonecrosis, recent trauma, etc.) or poor general health status that would interfere with the functional assessments during the study.

Design outcomes

Primary

MeasureTime frame
womac;

Countries

China

Contacts

Public ContactXiong Guo
guox@mail.xjtu.edu.cn+86 029 87655621

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 1, 2026